SRTAStrata Critical Medical, Inc.
The Read
SRTA's stock historically reacted with a median absolute move of ~19%.
The schedule
- Thu15Oct
Market digestion of anticipated updates to Organ Procurement and Transplantation Network (OPTN) and CMS reimbursement rates.
- Fri12Feb
Q3 results acting as a critical valuation reset test, focusing on sustained revenue growth and margin defense.
- Sun14Feb
Full-year 2026 wrap-up and issuance of the critical FY27 revenue and CapEx guidance.
- Mon1Mar
Strategic investor update detailing aircraft acquisition timelines, healthcare IT integrations, and network expansion plans.
- Wed5May
Past
- Tue1Sep
Assessment of potential equity or convertible debt financing to fund fleet expansion and aviation technology upgrades.
- Tue11Aug
Q2 earnings report to test sustainability of Q1's return to net profitability ($2.49M) against a stretched pre-event valuation.
- Wed1Jul
Potential announcement of new Organ Procurement Organization (OPO) or hospital network logistics contracts.
- Mon15Jun
Actual outcome: Mixed · $5.88 at outcome
Despite an initial 8.5% surge on June 16, the stock finished flat by the outcome date as the market weighed macro headwinds related to fuel costs and healthcare policy. Although Strata later announced a $21.5 million acquisition of a national organ recovery program on June 24 to expand its clinical business, the stock failed to sustain momentum and drifted lower by early July.
Market evaluation of volatile aviation fuel costs and evolving CMS/ACA policies under the Trump Administration, directly impacting medical transport operating margins.
- Wed6May
Actual outcome: Bull · $5.43 at outcome
Strata Critical Medical reported Q1 2026 EPS of -$0.11, exactly meeting analyst estimates in its first quarter as a pure-play medical logistics company. The in-line results, combined with the recent strategic acquisition of Ohio Valley Perfusion Associates and the expiration of outstanding warrants, reassured investors of the company's focused growth trajectory and clearer capital structure. This confidence drove the stock past the $5.20 bull target to close at $5.43 by the outcome date, with shares continuing to climb in the following weeks.
Strata Critical Medical reports Q1 2026 results around a $4.5 starting point, the first clean quarter where investors expect the refocused medical logistics model to translate into more stable revenue, improving unit economics, and clearer visibility on the cash burn trajectory.
- Thu30Apr
Actual outcome: Bull · $5.33 at outcome
Strata Critical Medical's stock surged past the bull target, driven by its Q1 2026 earnings meeting EPS estimates and positive strategic developments. The rally was further fueled by the April 30 acquisition of Ohio Valley Perfusion Associates, which expanded the company's regional footprint, alongside favorable market dynamics in the broader organ transport sector.
Tandem competitor TMDX reports earnings and updates on transplant logistics volumes, giving the market a fresh read on growth, pricing, and margins for organ transport and critical medical aviation services that directly frame expectations for Strata Critical Medical around $4.05.
- Tue24Mar
Actual outcome: Bear · $4.18 at outcome
Price reached or fell below bear floor ($3.50) at outcome date.
Release of fiscal year 2025 results and management's forward guidance for the recovery of contracting revenue.
- Tue3Mar
Actual outcome: Bear · $4.35 at outcome
Strata Critical Medical reported Q4 2025 results with in-line EPS of -$0.11 and an 83.5% year-over-year revenue increase to $66.8 million. Despite the strong top-line growth and a 39.5% increase in logistics gross profit, the company posted a full-year net loss of $20.1 million from continuing operations, which weighed on investor sentiment and drove a 9.4% decline in the stock.
Release of fiscal year results following a massive -58% YoY revenue decline. Focus shifts entirely to the medical logistics pivot.
